Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Jan 18:13:1099451.
doi: 10.3389/fendo.2022.1099451. eCollection 2022.

Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01)

Cesare C Berra  1 , Maria Chiara Rossi  2 , Marco Mirani  3 , Daniela Ceccarelli Ceccarelli  4 , Cristina Romano  5 , Lorenza Sassi  5 , Elena Peretti  5 , Giuseppe Favacchio  3 , Ida Pastore  6 , Laura Folini  1 , Giusi Graziano  2 , Maria Elena Lunati  6 , Sebastiano Bruno Solerte  4 , Paolo Fiorina  6   7
Affiliations
Observational Study

Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01)

Cesare C Berra et al. Front Endocrinol (Lausanne). .

Abstract

Introduction: Aim of the present study was to evaluate the real-world impact of once-weekly (OW) subcutaneous semaglutide on different end-points indicative of metabolic control, cardiovascular risk factors, and beta-cell function in type 2 diabetes (T2D).

Methods: This was a retrospective, observational study conducted in 5 diabetes clinics in Italy. Changes in HbA1c, fasting blood glucose (FBG), body weight, blood pressure, lipid profile, renal function, and beta-cell function (HOMA-B) during 12 months were evaluated.

Results: Overall, 594 patients (97% GLP-1RA naïve) were identified (mean age 63.9 ± 9.5 years, 58.7% men, diabetes duration 11.4 ± 8.0 years). After 6 months of treatment with OW semaglutide, HbA1c levels were reduced by 0.90%, FBG by 26 mg/dl, and body weight by 3.43 kg. Systolic blood pressure, total and LDL-cholesterol significantly improved. Benefits were sustained at 12 months. Renal safety was documented. HOMA-B increased from 40.2% to 57.8% after 6 months (p<0.0001).

Discussion: The study highlighted benefits of semaglutide on metabolic control, multiple CV risk factors, and renal safety in the real-world. Semaglutide seems to be an advisable option for preservation of β-cell function and early evidence suggests it might have a role in modifying insulin resistance (HOMA-IR), the pathogenetic basis of prediabetes and T2D.

Keywords: HbA1c; beta-cell function; cardiovascular risk factors; effectiveness; insulin resistance; semaglutide; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

MR has received funding for research from NovoNordisk, Sanofi, Alfasigma, Artsana, AstraZeneca, Johnson&Johnson, Medtronic, Shionogi, SOBI, Meteda and Theras. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Changes in estimated mean levels of HbA1c after 6 and 12 months from semaglutide initiation.
See this image and copyright information in PMC

References

    1. An J, Nichols GA, Qian L, Harrison TN, Li Z, Munis MA, et al. . Time in suboptimal glycemic control over 10 years for patients newly diagnosed with type 2 diabetes. J Diabetes Complications (2020) 34(8):107607. doi: 10.1016/j.jdiacomp.2020.107607 - DOI - PubMed
    1. SID-AMD standard italiani per la cura del diabete mellito (2018). Available at: https://aemmedi.it/wp-content/uploads/2009/06/AMD-Standard-unico1.pdf.
    1. American Diabetes Association Professional Practice Committee. Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, et al. . Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2022. Diabetes Care (2022) 45(Suppl 1):S125–43. doi: 10.2337/dc22-S009 - DOI - PubMed
    1. Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol (2018) 14(7):390–403. doi: 10.1038/s41574-018-0016-2 - DOI - PubMed
    1. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia (1993) 36(8):741–4. doi: 10.1007/BF00401145 - DOI - PubMed

Publication types